ACE2 and COVID-19: The use of these two angiotensin system modulators in clinical management of COVID-19 has taken center stage due to controversial findings in animal studies that show increase in ACE2 expression with use of the ACEI, lisinopril, or ARBs, losartan, at doses that are much higher than that prescribed to patients 156.